Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants

NCT05082285 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05082285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2021
Completion date
March 31, 2025
Enrollment
726 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal